Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison with the BioFire Respiratory Panels 2 and 2.1 (RP2 and RP2.1; bioMérieux, Marcy l’Étoile, France), using 147 nasopharyngeal swabs. The limit of detection (LOD) of the PowerChek assay was determined using SARS-CoV-2, influenza A, and B RNA standards. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B were 1.12, 1.24, and 0.61 copies/μL, respectively. The positive and negative percent agreements of the PowerChek assay compared with RP2 and RP2.1 were 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The performance of the PowerChek assay was comparable to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections.
Keywords: Agreement; Influenza; Influenza A&B; Multiplex Real-Time PCR Kit; Performance; PowerChek SARS-CoV-2; Real-time PCR; SARS-CoV-2.
【저자키워드】 SARS-CoV-2, Influenza, Real-time PCR, agreement, performance, Influenza A&, B, Multiplex Real-Time PCR Kit, PowerChek SARS-CoV-2, 【초록키워드】 SARS-CoV-2, Influenza, severe acute respiratory syndrome coronavirus-2, Influenza virus, severe acute respiratory syndrome Coronavirus, influenza A, Severe acute respiratory syndrome, PCR, Real-time PCR, nasopharyngeal swabs, limit of detection, France, influenza viruses, respiratory, influenza B, Coronavirus-2, bioMérieux, Healthcare system, acute respiratory syndrome, acute respiratory syndrome coronavirus, diagnosing, positive, RNA standards, influenza infections, evaluated, was determined, comparable, Panel, RP2, 【제목키워드】 SARS-CoV-2, PCR, respiratory, Panel,